Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07198802

Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma

To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2~3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Nasopharyngeal Carcinoma (NPC) Carcinoma Head and Neck Neoplasms Nasopharyngeal Carcinoma Nasopharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Pharyngeal Diseases Pharyngeal Neoplasms Stomatognathic Diseases

Age range

15 year–75 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Before the trial, the participants must meet all of the following requirements to be eligible for inclusion.

  • Clearly diagnosed with nasopharyngeal carcinoma by pathology;
  • Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital;
  • Patients diagnosed in our hospital from January 2025 to December 2028;
  • Have relatively complete clinical data;
  • Age between 15 and 75 years old;

Exclusion criteria

Before the trial, the participants who meet any of the following requirements cannot be included.

  • The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.;
  • The participants failed to obtain pathological and imaging data for various reasons;
  • Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.

Treatment and study plan

No intervention

Other

This project involves no therapeutic intervention for the subjects.

Primary outcomes

  1. Failure-free survival (FFS)

    Time frame: 3-year

    Failure-free survival is measured from day of diagnosis until treatment failure, death from any cause, or last follow-up visit, whichever occurred first

Secondary outcomes

  1. Overall survival (OS)

    Time frame: 5-year

    Overall survival is measured from day of diagnosis until death due to any cause or the latest known date alive

Sponsors and collaborators

Lead sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Other

Registry information

Official study title

Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma Based on Tumor Immune Microenvironment

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Sep 30, 2025
Registry last updated
Sep 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.